EuroQuity Blog

Join the InvestHorizon e-pitch Session on September the 18th at 5:00pm

The next InvestHorizon pitch session will be held online on September 18th, at 5PM CEST. Six European start-up are looking for funding.

Our next InvestHorizon pitch session will be held online on September 18th at 5:00 PM CEST.
6 companies will be presented.
All these Serie A medtech companies are part of the European InvestHorizon acceleration program, and are looking for funds to continue their growth.

Register here  - Do not hesitate to share to syndicate with your colleagues.

Here is the first list of deeptech companies:


Thermotherapy for Treatment of Cancer
The company offers a new approach to thermotherapy for treatment of cancer. It increases efficacy of radio- or chemotherapy up to 50%. Thermotherapy has no negative side effects for patients. They use microwave antennas with precision control through software to heat the tumor. Nearby sensitive organs are fenced off from the heat. Therefore, it can be used on many tumor types, even deep within the body. The patented technology is unmatched in industry.
Patented proven clinical prototype; 70 patients treated; Community of 10 clinics | €6 M sought - Tranche 1: €3.2 M - Tranche 2: €2.8 M
Robotic Assisted Rehabilitation
The company is developing and supplying solutions to the emerging market of robotic assisted rehabilitation (RAR) services, using the most advanced technology in their robotic devices, integrating electronics, mechatronics, informatics and telecommunication technologies. They develop a wearable robotic device for knee rehabilitation. It incorporates “assisted as needed” control and functional electrical stimulation (FES) features, helping to speed-up and to improve the rehabilitation process. 
Preliminary contacts to check market acceptance have been carried out with posi6ve results| €1.5 M sought            
Physiological diagnostics and therapy
The company has participated in several medical instrument development projects and implemented cardiovascular and pulmonological technologies.
The innovation offers integrated solutions in any of the domains of CVD prevention and early diagnostics, remote care and rehabilitation for many people.
Number of customers approx. 60.000 in Year5 | €2.5 M sought
Bio-wearables Health
An advanced bio-wearable company currently working on its innovative technology. This technology will allow the analyze of key physiological markers by simply “tasting” the skin rather than analyzing blood samples.
It will enable a precise and continuous monitoring of systemic glucose level anytime and anywhere.
Excellent results in 1st preclinical animal study, > 99% accuracyPreclinical; CE mark expected mid 2022 | €10 M sought
Biotech – Phenylketonuria
A biotech company aiming to develop novel therapies to treat diseases caused by protein misfolding. Their first disease target is phenylketonuria (PKU), a rare genetic disease of metabolism. The development program is based on the company's intellectual property on the screening and development of small molecule pharmacological chaperones with the potential to stabilize/maintain the native structure of the protein involved in the disease.
Promising proof of principle in vitro and in vivo, with line of sight to a de-risked preclinical candidate | €2.5 M sought
Healthtech – Heart Diseases
The company aims to develop biomedical technology (software and devices) for children with heart diseases. Product line includes patented powerless pediatric asset devices and heart valves already tested in patients. The company also provides blood flow design platforms for cardiovascular surgeons tested in patients. These interactive tools allow surgeons to predict the outcome of their intended operations prior to the actual surgery.
50 surgeons had interest | €500 K sought

Register here  !

Rédigé par Baptiste Baudouin le Monday, September 9th 2019
Stay informed by suscribing to our newsletter